Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARGARET VON MEHREN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1144243858
CMS profile
233516
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,481.32

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,480.00 2
Food and Beverage $1.32 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $1,980.00 1
PFIZER INC. $1,501.32 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARGARET VON MEHREN

NPI 1144243858 · CMS profile ID 233516

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $3,481.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $1,980.0005/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686543021 CMS
PFIZER INC. $1,500.0001/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673757429 CMS
PFIZER INC. $1.3201/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673262617 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,481.32 3
PY2022 $16,889.37 14
PY2024 $17,850.01 21
PY2025 $107.49 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $439.96 2
PY2025 Principal investigator $3,999,133.04 151
PY2024 Principal investigator $2,114,235.16 59
PY2023 Principal investigator $1,626,861.83 207
PY2022 Recipient $12,046.00 1
PY2022 Principal investigator $1,964,612.75 261
PY2021 Principal investigator $4,056,403.36 219
PY2020 Recipient $1,210.00 1
PY2020 Principal investigator $2,320,213.22 69
PY2019 Principal investigator $1,242,313.06 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

207 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 12/15/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053739833
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 12/15/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053739835
Principal investigator 1 Deciphera Pharmaceuticals Inc. $130,350.00 12/14/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053739817
Principal investigator 1 Sumitomo Pharma America, Inc. $1,000.00 12/14/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A Phase 1, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287Administered Twice Daily to Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1146113579
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 11/08/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053739507
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 11/08/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053739513
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 11/08/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053739519
Principal investigator 1 Deciphera Pharmaceuticals Inc. $130,350.00 11/02/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053739455
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 11/01/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053739334
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 11/01/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053739339
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 11/01/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053739345
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053724425
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053724435
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053724443
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724451
Principal investigator 1 Deciphera Pharmaceuticals Inc. $250.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724459
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724467
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724477
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724485
Principal investigator 1 Deciphera Pharmaceuticals Inc. $250.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724493
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724503
Principal investigator 1 Deciphera Pharmaceuticals Inc. $250.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724511
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,637.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724519
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724527
Principal investigator 1 Deciphera Pharmaceuticals Inc. $250.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724537
Principal investigator 1 Deciphera Pharmaceuticals Inc. $250.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724545
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724553
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 10/19/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) No dispute reported 06/30/2026 1053724561
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 10/13/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738927
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 10/13/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738931
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,506.00 10/13/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738937
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738467
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738473
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738479
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738485
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738491
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738497
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738505
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738509
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738515
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738521
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738527
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738533
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738539
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738545
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738551
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738557
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738563
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738567
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738573
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738579
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738585
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738591
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738595
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738601
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738607
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738613
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738619
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738625
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 10/11/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053738631
Principal investigator 1 Novartis Pharmaceuticals Corporation $243,355.61 10/05/2023 Covered Recipient Teaching Hospital
Dana-Farber Cancer Institute
Phase II trial of Ribociclib in combination with Everolimus in advanced dedifferentiated liposarcoma DDL and leiomyosarcoma LMS No dispute reported 06/30/2026 1017202787
Principal investigator 1 Deciphera Pharmaceuticals Inc. $720.00 09/07/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053737287
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,205.00 09/07/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053737295
Principal investigator 1 Deciphera Pharmaceuticals Inc. $720.00 09/07/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053737303
Principal investigator 1 Deciphera Pharmaceuticals Inc. $720.00 09/07/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053737313
Principal investigator 1 Deciphera Pharmaceuticals Inc. $24.00 09/07/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053737321
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,459.20 07/26/2023 Covered Recipient Teaching Hospital
American Oncologic Hospial
An open label multi center imatinib rollover protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatinib treatment No dispute reported 06/30/2026 1017211765
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053728965
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053728967
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053728973
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053728977
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053728987
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053728993
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729007
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729013
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729025
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729033
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729045
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729047
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729053
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729055
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729059
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729071
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729087
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729099
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729125
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729133
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729147
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729149
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729151
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729155
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729159
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729167
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729169
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729185
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729215
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729219
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729227
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729237
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729259
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729261
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729263
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729271
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729277
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729283
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729287
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729303
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729305
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729313
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,723.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729315
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729319
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729325
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729329
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729337
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729341
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729345
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729349
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729351
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729353
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729355
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729359
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729361
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729367
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729377
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729385
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729387
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729393
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729395
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729403
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729417
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729423
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729437
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729447
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729449
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729455
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729457
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729461
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729465
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729471
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,416.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729475
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729479
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729495
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729501
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729515
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729519
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729531
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729537
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729545
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729553
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729559
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729561
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729563
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729567
Principal investigator 1 Deciphera Pharmaceuticals Inc. $276.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729571
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729573
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729579
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729587
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729593
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729595
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729603
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729611
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729613
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729617
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729627
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729635
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729637
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729647
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729649
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729659
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729675
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729687
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729709
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,965.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729717
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729721
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729753
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729765
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729771
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729775
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,821.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729781
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729787
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,361.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729791
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729797
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729805
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729807
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729829
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729833
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729845
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729847
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729853
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729863
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729875
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729881
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729887
Principal investigator 1 Deciphera Pharmaceuticals Inc. $23.00 05/15/2023 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1053729897
Principal investigator 1 Novartis Pharmaceuticals Corporation $241,288.90 05/08/2023 Covered Recipient Teaching Hospital
Dana-Farber Cancer Institute
Phase II trial of Ribociclib in combination with Everolimus in advanced dedifferentiated liposarcoma DDL and leiomyosarcoma LMS No dispute reported 06/30/2026 1017202555
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,500.00 02/21/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053724365
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 02/21/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053724373
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 02/21/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053724385
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 02/21/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053724393
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 02/21/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053724401
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 02/21/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053724409
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 02/21/2023 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1053724417
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 02/10/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
MASTER PROTOCOL TO ASSESS THE SAFETY AND RECOMMENDED PHASE 2 DOSE OF N No dispute reported 06/30/2026 1006223953
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 02/10/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
MASTER PROTOCOL TO ASSESS THE SAFETY AND RECOMMENDED PHASE 2 DOSE OF N No dispute reported 06/30/2026 1006224181
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 02/10/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
MASTER PROTOCOL TO ASSESS THE SAFETY AND RECOMMENDED PHASE 2 DOSE OF N No dispute reported 06/30/2026 1006224193
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 02/10/2023 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
MASTER PROTOCOL TO ASSESS THE SAFETY AND RECOMMENDED PHASE 2 DOSE OF N No dispute reported 06/30/2026 1006224203
Principal investigator 1 Novartis Pharmaceuticals Corporation $404,517.12 01/10/2023 Covered Recipient Teaching Hospital
American Oncologic Hospial
An open label multi center imatinib rollover protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatinib treatment No dispute reported 06/30/2026 1017211487